Dechert LLP represented ABAXIS Europe GmbH in its acquisition of 100% of the capital stock of Quality Clinical Reagents Limited (QCR) and Trio Diagnostics (Ireland) Limited (Trio Diagnostics) both headquartered in York, United Kingdom. The sellers consisted of private investors (75%) and Veterinary Solutions Limited (25%), a subsidiary of the United States veterinarian wholesale company Henry Schein, Inc.

ABAXIS Europe GmbH is a wholly owned subsidiary of ABAXIS, Inc., a NASDAQ-listed company headquartered in Union City, California, United States with a market capitalization of more than 1 billion euros. ABAXIS, Inc. is a leading producer of technical instruments for human and veterinary medicine. QCR and Trio Diagnostics specialize in the supply of laboratory instrumentation and consumables to the veterinary profession.

The Dechert advisory team included Frankfurt attorneys Dr. Markus J. Friedl (lead), Sven Schulte-Hillen, both Corporate, Dr. Martin Haisch (Tax), Gottfried Bassewitz (Corporate), Laura Titze (Antitrust/Competition) in additional to London attorneys Graham Defries, Jodie Valler-Feltham, Rhodri Owen (Corporate), Charles Wynn-Evans, Edward Holmes, Harraj Panesar (Employment), Scott Curtis, Isaac Bordon, and David Gervais (Real Estate Finance).